Expression of ER/PR/HER2, basal markers and adhesion molecules in primary breast cancer and in lymph nodes metastases: A comparative immunohistochemical analysis

Polish Journal of Pathology

Volumn 63, Issue 4, 2012, Pages 228-234

  Adamczyk, Agnieszka ^a   Niemiec, Joanna ^a   Ambicka, Aleksandra ^b   Małecki, Krzysztof ^c   Wysocki, Wojciech H ^b   Mituś, Jerzy ^b   Ryś, Janusz ^b  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Centre of Oncology Maria Skłodowska Curie Memorial Institute   (Poland)

^c University Children Hospital of Cracow   (Poland)

Author keywords

Adhesion molecules; Basal markers; Lymph node metastasis; Primary breast tumour

Indexed keywords

CELL ADHESION MOLECULE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL ADHESION MOLECULES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84873828310     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/PJP.2012.32769     Document Type: Article

References (25)

1. Chen LC, Kurisu W, Ljung BM, et al. Heterogeneity for allelic loss in human breast cancer. J Natl Cancer Inst 1992; 84: 506-10.
2. Davidoff AM, Kerns BJ, Iglehart JD, et al. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991; 51: 2605-10.
3. Iglehart JD, Kerns BJ, Huper G, et al. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat 1995; 34: 253-263.
4. Lacroix H, Iglehart JD, Skinner MA, et al. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 1989; 4: 145-51.
5. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St, Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
6. Olafsen T, Sirk SJ, Olma S, et al. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour Biol 2012; 33: 669-677.
7. Wang K, Wang K, Li W, et al. Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol 2009; 50: 1095-1103.
8. Heine M, Freund B, Nielsen P, et al. High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PLoS One 2012; 7: e36258.
9. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49-54.
10. Tsutsui S, Ohno S, Murakami S, et al. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. Eur J Surg Oncol 2002; 28: 383-387.
11. D'Andrea MR, Limiti MR, Bari M, et al. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res Treat 2007; 101: 279-284.
12. Bogina G, Bortesi L, Marconi M, et al. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 2011; 459: 1-10.
13. Cho EY, Han JJ, Choi JL, et al. Comparison of Her-2, EGFR and Cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study. J Korean Med Sci 2008; 23: 1053-1061.
14. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005; 103: 1763-1769.
15. Aoyama K, Kamio T, Nishikawa T, et al. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes. Jpn J Clin Oncol 2010; 40: 613-619.
16. Santinelli A, Pisa E, Stramazzotti D, et al. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008; 122: 999-1004.
17. Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012; 30: 593-599.
18. Aboliņš A, Vanags A, Trofimovičs G, et al. Molecular subtype shift in breast cancer upon trastuzumab treatment: a case report. Pol J Pathol 2011; 62: 65-68.
19. Grupka NL, Lear-Kaul KC, Kleinschmidt-DeMasters BK, et al. Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/ neu status. Arch Pathol Lab Med 2004; 128: 974-979.
20. Shao MM, Liu J, Vong JS, et al. A subset of breast cancer predisposes to brain metastasis. Med Mol Morphol 2011; 44: 15-20.
21. Takes RP, Baatenburg de Jong RJ, Wijffels K, et al. Expression of genetic markers in lymph node metastases compared with their primary tumours in head and neck cancer. J Pathol 2001; 194: 298-302.
22. Popławski AB, Jankowski M, Erickson SW, et al. Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression. Eur J Hum Genet 2010; 18: 560-568.
23. Ellsworth RE, Seebach J, Field LA, et al. A gene expression signature that defines breast cancer metastases. Clin Exp Metastasis 2009; 26: 205-213.
24. Weigelt B, Wessels LF, Bosma AJ, et al. No common denominator for breast cancer lymph node metastasis. Br J Cancer 2005; 93: 924-932.
25. Weigelt B, Glas AM, Wessels LF, et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003; 100: 15901-15905.